Ahmed El Bastawisy
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 5
Publications (10 Years): 5
Publications
- Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, Yeşim Eralp, Yoon Sim Yap, Seock-Ah Im, Julie Rihani, Erhan Gokmen, Ahmed El Bastawisy, Nuri Karadurmus, Yueh Ni Lim, Chun Sen Lim, Le Thanh Duc, Wei-Pang Chung, Govind Babu K, Konstantin Penkov, James Bowles, Teresa Delgar Alfaro, Jiwen Wu, Melissa Gao, Khemaies Slimane, Nagi S El SaghirFinal Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (23) (2024)
- Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, Yeşim Eralp, Yoon Sim Yap, Seock-Ah Im, Julie Rihani, Erhan Gokmen, Ahmed El Bastawisy, Nuri Karadurmus, Yueh Ni Lim, Chun Sen Lim, Le Thanh Duc, Wei-Pang Chung, Govind Babu K, Konstantin Penkov, James Bowles, Teresa Delgar Alfaro, Jiwen Wu, Melissa Gao, Khemaies Slimane, Nagi S El SaghirFinal Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (23) (2024)
- Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, Yeşim Eralp, Yoon Sim Yap, Seock-Ah Im, Julie Rihani, Erhan Gokmen, Ahmed El Bastawisy, Nuri Karadurmus, Yueh Ni Lim, Chun Sen Lim, Le Thanh Duc, Wei-Pang Chung, Govind Babu K, Konstantin Penkov, James Bowles, Teresa Delgar Alfaro, Jiwen Wu, Melissa Gao, Khemaies Slimane, Nagi S El SaghirFinal Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
- Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, Yeşim Eralp, Yoon Sim Yap, Seock-Ah Im, Julie Rihani, Erhan Gokmen, Ahmed El Bastawisy, Nuri Karadurmus, Yueh Ni Lim, Chun Sen Lim, Le Thanh Duc, Wei-Pang Chung, Govind Babu K, Konstantin Penkov, James Bowles, Teresa Delgar Alfaro, Jiwen Wu, Melissa Gao, Khemaies Slimane, Nagi S El SaghirFinal Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (23) (2024)
- Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, Yeşim Eralp, Yoon Sim Yap, Seock-Ah Im, Julie Rihani, Erhan Gokmen, Ahmed El Bastawisy, Nuri Karadurmus, Yueh Ni Lim, Chun Sen Lim, Le Thanh Duc, Wei-Pang Chung, Govind Babu K, Konstantin Penkov, James Bowles, Teresa Delgar Alfaro, Jiwen Wu, Melissa Gao, Khemaies Slimane, Nagi S El SaghirFinal Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (23) (2024)